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Background: Nowadays, there is increasing awareness about the frequent chronic comorbidities 
in patients with chronic obstructive pulmonary disease (COPD) but little information is available 
to quantify the burden of illness that these conditions cause in this population. We aimed to 
identify and describe a population suffering from COPD highlighting the co-morbid conditions 
that may contribute to poor clinical outcomes.
Design: Epidemiological cross-sectional study conducted using administrative heath services 
databases.
Results: A cohort of 126,283 COPD patients was identiﬁ  ed. The estimated prevalence in 
adult population was 3.6%. Ninety-eight percent of these patients (123,603) received at least 
one prescription of “non-respiratory drugs” and, considering chronic speciﬁ  c comorbidities 
(cardiovascular disease, diabetes and depression) 86,351 patients (68.4% of COPD patients) 
suffered from at least one of these conditions. 80,840 pts (64.4%) were treated for cardiovascular 
diseases, 17,091 subjects for diabetes (12.4%) and 10,292 for depression (8%). About 16% of 
COPD subjects (19,168 patients) had two out of the three considered comorbid conditions and 
1352 patients (1.1%) all three.
Conclusion: This study highlights the complex spectrum of comorbidities in COPD patients. 
The prevalence of main chronic diseases increases with age, in particular among female group. 
An enhanced public awareness about these conditions is necessary, just as a more comprehensive 
approach in their management.
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Introduction
Nowadays, chronic obstructive pulmonary disease (COPD) is considered a major 
cause of morbidity and mortality worldwide. In contrast to the trend for cardiovas-
cular diseases, cancer and stroke, death rates from COPD have been rising steadily 
over the last decade (Hurd et al 2005) and, according to estimates of the World 
Health Organization (WHO), by 2020 this condition shall become the third most 
frequent cause of death, following coronary and cerebrovascular disease (Murray 
et al 1997).
Although these ﬁ  gures on COPD morbidity and mortality are alarming, they are 
only a “tip of the iceberg” because COPD is often part of a much more complex proﬁ  le 
of comorbidities (Hansell et al 2003).
Over the last few years, there has been an increased awareness about the systemic 
nature of COPD (Augusti 2005; Shapiro et al 2005) and the frequent and important 
chronic comorbidities that may contribute signiﬁ  cantly to its severity and mortality 
(van Manen et al 2001; Boyd et al 2005; Sin and Man 2005a; Soriano et al 2005), and 
that might be affected by treatment (Liao 2005; Sin and Man 2005b).International Journal of COPD 2007:2(4) 568
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Several studies suggest that cardiovascular diseases 
(CVD) are more frequent in COPD patients than in the gen-
eral population and may represent a burden greater than that 
of lung disease itself (Burney et al 2003; Holguin et al 2005; 
Huiart et al 2005). Moreover, Antonelli and colleagues docu-
mented that in the presence of ischemic heart diseases CVD 
becomes an important factor, predicting all-cause mortality 
on COPD patients (Antonelli et al 1997).
In addition, among COPD comorbidity, depression 
deserves particular attention. COPD (especially at severe 
levels) leads to impairments in activities of daily living, social 
and psychological functioning and recreational activities. 
Depression has been found to occur in 7%–42% of COPD 
patients up to four times more frequently than in subjects 
without COPD (Kunik et al 2005).
These observations highlight the fragmentary nature 
of available information, and at the same time the impor-
tance of studying COPD comprehensively, considering 
often-associated concomitant conditions and quantifying 
the burden of illness that these conditions cause in this 
population.
With this study we intend to identify a population suf-
fering from COPD, assessing COPD prevalence in a large 
sample of Italian population (about 8 millions of inhabitants) 
and describing the general proﬁ  le of COPD patients, in whom 
comorbidity plays an important role.
Methods
This is an epidemiological cross-sectional study, conducted 
using administrative heath services databases from 22 Italian 
Local Health Units (LHU) participating in the ARNO project 
(Clavenna et al 2003). The population comprised 7,731,628 
inhabitants. The observation was carried out between January 
1st and December 31st, 2004.
Data sources
This study used the outpatients’ prescriptions database (PD) 
of drugs totally or partially reimbursed by the National Health 
System (NHS), and the Civil Registry Database (CRD), in 
each LHU.
These databases have been extensively used for epidemio-
logical studies including drug-exposure and chronic disease 
(Clavenna et al 2003; Anecchino et al 2005) as well as to 
study population-based health outcomes (Monte, Fanizza, 
et al 2006; Monte, Macchia, et al 2006). Besides, the use 
of this source limits bias selection as these databases cover 
the whole population. 69% of residents were eligible for 
outpatient prescription drug beneﬁ  ts.
All databases are managed by the Consorzio Interuni-
versitario CINECA.
Cohort deﬁ  nition
COPD cohort was identiﬁ  ed using the following criteria:
•  Age of 45 years or above;
•  Chronic treatment with drugs for obstructive pulmonary 
diseases (inhaled/oral bronchodilators, inhaled steroids 
or ﬁ  xed-dose combinations) (index drugs).
Chronicity was deﬁ  ned linking the number of prescribed 
packages and the duration of therapy, deﬁ  ned in terms of 
time from ﬁ  rst to last prescription of the index drug. Patients 
who received more than ﬁ  ve boxes of the index drug for over 
3 months or more were considered chronically treated.
A treatment with antibiotics and/or oral steroids was 
assumed as an indicator of disease exacerbations.
To assess the presence of comorbidities, the prescriptions 
of drugs different from those for COPD were analysed. In 
particular, we focused on three drugs classes identifying 
speciﬁ  c co-morbidities: diabetes (insulin, insulin analogues 
and oral hypoglycaemic therapy), cardiovascular diseases 
(any cardiovascular drug) and depression (selective sero-
tonin reuptake inhibitors, monoamine oxidase inhibitors, 
monoamine uptake inhibitors).
Treatment chronicity was explored for cardiovascular and 
antidepressant drugs, assuming as chronic any treatment with 
more than three boxes over 3 or more months.
Statistical analysis
We used descriptive statistics to examine the epidemiologi-
cal and therapeutic characteristics of our sample. Prevalence 
of estimated COPD was deﬁ  ned as the number of patients 
receiving one or more COPD index drugs per 100 individuals 
in the population. Prevalence rates, as well as percentages 
of patients with comorbidities have been stratiﬁ  ed by age 
and gender.
Results
Among the population examined of 7,731,628 NHS users, 
3,535,371 (46%) were of 45 years and over. Of these, 462,894 
(13%) patients were exposed to at least one respiratory agent 
(COPD index drug). The composition of these two popula-
tions is reported in Table 1.
On the basis of the criteria above described and the ﬂ  ow-
chart represented in Figure 1, a cohort of 126,283 COPD 
patients was identiﬁ  ed.
The prevalence of COPD in our adult population 
(45 years) was 3.6% and it increased greatly with age (1.9% International Journal of COPD 2007:2(4) 569
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in the age group 45–64, 4.8% in 65–74, 6.8% in 75–84 and 
5.6% in 85 years). COPD appeared more common in males 
than in females (4.1% in males and 3.1% in females). This differ-
ence was particularly evident in the age group 75–84 years, while 
in the youngest there was no gender difference (Figure 2).
Main characteristics of the patients
Table 2 reports the main characteristics of COPD patients 
including pharmacological treatment and general clinical 
proﬁ  le.
The cohort with COPD was older than the reference 
population (see Table 1). Almost 70% of the patients (88,261) 
were 65 or older, including 8% 85 years. The mean age 
was 70 years. Fifty-two percent (65,869) were male.
A high proportion of patients (80%) received a 
poly-therapy as COPD treatment, and, in particular, 
67,822 patients (54%) received more than three different 
drugs.
Likewise, about 80% (100,430 patients) were treated with 
drugs indicating exacerbations. Antibiotic treatment (with or 
without oral corticosteroids) was the most common: three 
fourths of the patients (94,869) were prescribed these drugs.
Comorbidities therapy
Ninety-eight percent of COPD patients (123,603) received at 
least one prescription of “non-respiratory drugs”; the main 
therapeutic classes used are presented in Table 3. These data 
highlight the clinical complexity of the COPD population, 
highly exposed to different pharmacological agents, from 
antibiotic or cardiovascular drugs (more than 70%) to nervous 
system agents (24%).
Considering speciﬁ  c comorbid conditions such as car-
diovascular disease, diabetes and depression and applying 
the chronicity criteria for therapy quoted above (see Method 
section), 86,351 patients (68.4% of COPD patients) suffered 
from at least one of these conditions.
Cardiovascular diseases, as expected in these age groups, 
were the most common condition coexisting in COPD 
patients (80,840 pts, 64.4%). 17,091 subjects were treated 
for diabetes (12.4% of COPD patients) and 10,292 for 
Table 1 General description of the examined population 
  Population     Patients exposed to 1
 ( 45 years)     respiratory drugs
Gender  N pts  %  N pts  %
 Male  1,603,364  45  205,711  44
 Female  1,932,007  55  257,183  56
Age      
 45–64  1,965,547  56  207,721  45
 65–74  810,721  23  128,398  28
 75–84  571,129  16  99,174  21
  85 187,974  5  27,601  6
Total 3,535,371  100  462,894  100
Figure 1 Flowchart of COPD patients’ identiﬁ  cation.
Panel patients 
7,731,628
Panel patients ≥45yrs of age 
3,535,371 (46.0%) 
Patients treated with at least one drug 
2,910,173 (82.3%) 
Patients with at least one index drug 
462,894 (15.9%) 
Patients chronically treated: “COPD patients”
126,283International Journal of COPD 2007:2(4) 570
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depression (8%). The percentage of patients suffering from 
these conditions increased with age (Figure 3).
This is particularly evident for cardiovascular diseases 
(about 40% in the age group 45–64 and over 80% in those 
85 years); the same is true also for depression (6.2% among 
patients 45–64 years old and 10.8% among those 85 years) 
(Figure 3). Although overall depression was more common in 
females than in males (5.9% in males and 10.6% in females), the 
increase with age was more marked among male patients (from 
3.9% to 8.2% in male vs from 8.3% to 12.8 in female) (Figure 3). 
A less remarkable increase was observed for diabetes (9.2% 
in the age group 45–64 and 13.7% in 85 years) without 
important gender differences (Figure 3). Interestingly, about 
16% of COPD subjects (19,168 patients) had two out of the 
three considered comorbid conditions and 1352 patients 
(1.1%) all three. The details of the different combinations 
are reported in Table 4.
These data document that about twenty thousand patients 
with impaired pulmonary function had a high risk proﬁ  le 
for the spectrum of comorbid diseases. The percentage of 
patients with the most complex proﬁ  le (all three diseases con-
sidered) indeed increased with age (0.5% of COPD patients 
45–64 years old, 1.1% of 65–74, 1.4% of 75–84 and 1.5% of 
patients 85 years). This increase was particularly evident 
in the female population (from 0.6% in younger patients to 
2.0% in older ones) (Figure 4).
Discussion
The ﬁ  rst and very important result of our study was the size 
of the sample identiﬁ  ed, 126,283 COPD patients, that was 
higher than any published COPD epidemiological studies 
(Halbert et al 2003), allowing the quantiﬁ  cation of the burden 
of COPD in the community setting, through an appraisal of 


























Figure 2 Prevalence estimated (%) of COPD in subgroups of patients differentiated in age and gender.
Table 2 Main characteristics of COPD patients
Characteristics N  pts  (126,283)  %
Gender
 male  65,869  52.2
 female  60,414  47.8
Age, yrs   
 45–64  38,022  30.1
 65–74  38,775  30.7
 75–84  38,929  30.8
  ≥85 10,557  8.4
Therapy with index drug   
 mono-therapy  25,778  20.4
 poly-therapy  100,505  79.6
Antibiotic agent – oral
steroid prescription
 yes  100,430  79.5
Non-index drug prescription
 yes  123,603  97.9
Speciﬁ  c comorbid condition
 yes  86,351  68.4
Table 3 Main therapeutic classes prescribed to COPD patients
Therapeutic class  Patients  % of COPD pts
Antibiotic agents  95,845  75.9
Cardiovascular drugs  92,367  73.1
Gastrointestinal and metabolic disorders  75,303  59.6
Musculoskeletal system  71,384  56.5
Blood and lymphatic system  55,922  44.3
Endocrine system  53,692  42.5
Nervous system  30,248  24.0International Journal of COPD 2007:2(4) 571
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This wide sample of COPD patients, identiﬁ  ed through 
a different methodology respect to the most recent surveys 
(Kim et al 2005; Menezes et al 2005), made possible to have 
numerically signiﬁ  cant subgroups, generally excluded in ran-
domized clinical trials and not particularly represented in sur-
veys: speciﬁ  cally, elderly subjects (up to 11,000 patients older 
than 85 years), patients with multiple comorbidities (almost 
20,000 patients chronically treated for at least two comorbid 
conditions); elderly females with very complex proﬁ  le (814 
patients with the three comorbidities considered).
These results are in agreement with the recent recommen-
dations (Curkendall et al 2006; Fabbri et al 2006) advocating 
efforts to characterize the spectrum of comorbid diseases and 
to develop a more comprehensive approach both in the study 
and in the management of COPD patients. In fact, despite the 
advances in the care of individuals with COPD, some uncer-
tainty remains about how best to manage patients, particularly 
elderly, with different chronic diseases. The information is 
limited and available studies tend to exclude patients with 
complex comorbidity (Boyd et al 2005; Fabbri et al 2006).
In our population we found that nearly all (98%) received 
other drugs besides respiratory agents. Antibiotic agents 
were the most common owing to the frequent bacterial 

























Female 40 68.8 79.8 85.4
Male 42.2 66.3 76.3 80.6
Female 8.3 10.1 13 12.8
Male 3.9 5.7 7.3 8.2
Female 8 14.6 16.1 14.9
Male 10.5 16 15.7 12.2




Figure 3 Percentage of COPD patients with comorbid conditions: diabetes, depression and cardiovascular diseases in subgroup of patients differentiated in sex and age.International Journal of COPD 2007:2(4) 572
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to cardiovascular, anti-inﬂ  ammatory, gastrointestinal agents 
highlights the frequent presence of different diseases in the 
same patient.
Our study has, however, some limitations. Administrative 
databases lack clinical and diagnostic information. We identi-
ﬁ  ed COPD patients and comorbidities only by prescription 
patterns and the distinction between COPD and asthma is 
difﬁ  cult in this context.
We limited misdiagnosis by including only subjects 
45 years or older and requiring more than occasional treatment. 
Misdiagnosis, therefore, certainly exists in our study but likely 
represents only a small portion of examined population.
Another limitation is that COPD may be under-diagnosed 
and therefore under-treated (Price et al 2003). Symptomatic 
and more severe patients are more likely to be chronically 
treated. Although the use of a general population protects 
from selection bias, our cohort likely comprised mostly 
patients with clear COPD, since we considered only inten-
sive drug exposure (about 80% of patients received two or 
more index drugs).
In people aged 45 years and older, we measured a COPD 
prevalence of 3.6%. These estimates could seem to be lower than 
those obtained in other population-based studies of COPD.
In Italy, Viegi and colleagues measured respectively a 
general COPD prevalence of 12.2%, 57.0% and 28.7% using 
three different COPD deﬁ  nitions (ERS, ATS and clinical) 
(Viegi et al 2000). However, this study included patients 
of every severity stage. Considering only moderate/severe 
COPD, the Viegi study rates result very similar to our data: 
3.6%, 5.2% and 4.4% respectively.
Our estimate is also lower than the range of 4%–10% 
derived from an international review of COPD prevalence 
(Halbert et al 2003), and than prevalence reported in the 
other European studies. In Greek people older than 35 years, 
Tzanakis reported a prevalence of 8.4% (Tzanakis et al 2004); 
in IBERPOC, a multicenter survey in Spain (Pena et al 2000), 
the prevalence was 13.1% for men and 10.5% for women. 
The explanation of these differences lies in the variety of 
criteria used to deﬁ  ne COPD.
The data available come from studies ad hoc with 
actively screened patients (using diagnostic methods, like 
spirometry), while our data derive from an analysis of 
treatment speciﬁ  cally of chronically treated patients.
If we apply less strict criteria, excluding chronicity or 
considering only older patients, our prevalence estimates 
Table 4 Detail of chronic comorbidities in COPD patients
Comorbidities  N pts  % of COPD pts
– Only one  65,831  52.1
  Cardiovascular  diseases  (CV)  60,500  47.9
  Diabetes  2,711  2.1
  Depression  2,620  2.1
– Two  19,168  15.2
  Diabetes  +  CV  12,848  10.2
  CV  +  Depression  6,140  4.9
  Diabetes  +  Depression  180  0.1
– Three  1,352  1.1
    Diabetes + CV + Depression  1,352  1.1















Female 124  251  319 120 814
Male 79 177  243 39 538
45-64 65-74 75-84 ≥85 total
% pts 
Figure 4 Percentage of COPD patients with all three pathologies (diabetes, depression, cardiovascular diseases) in subgroups of patients differentiated in age and gender.International Journal of COPD 2007:2(4) 573
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increase and become very close to literature estimates (see 
Table 1).
With respect to specific chronic comorbidities such 
as diabetes and cardiovascular diseases, our data are in 
perfect agreement with the literature. A recent study using 
administrative databases and identifying COPD patients 
according to our criteria, found a diabetes prevalence of 
14.5% (Curkendall et al 2006); Gudmundsson and col-
leagues (Gudmundsson et al 2006) reported a prevalence 
of 10.6% and 65% for diabetes and cardiovascular disease 
respectively.
On the contrary, our results on depression are difﬁ  cult 
to compare because of the wide variability in the available 
prevalence estimates (up to 42% in moderate to severe COPD, 
Yohannis et al 2000; Kunik et al 2005), even if van Manen et al 
who investigated prevalence of comorbidity in patients with 
COPD over 40 years of age (van Manen et al 2001), found a 
depression prevalence of 8.7%, very similar to our data.
In summary, this study, besides conﬁ  rming previous 
evidence, documents that COPD is a health problem also in 
Italy and that public awareness of its burden is important. 
From a broader perspective, it highlights the complex spec-
trum of comorbidities in COPD patients, underlining the 
importance of a comprehensive approach in their manage-
ment. Redelmeier and colleagues demonstrated that when the 
central focus of care is a serious condition, the care for other 
chronic disorders is compromised (Redelmeier et al 1998). 
This could be a real problem considering the high frequency 
of chronic comorbidities that may drastically worsen COPD 
severity and mortality and of complex elderly patients, whose 
management is still uncertain (Fabbri et al 2006).
In conclusion, we think that comorbidities should be 
considered when estimating the social and economic burden 
of disease and we hope that our results will increase the atten-
tion and the initiatives on COPD, possibly in agreement with 
more general actions on respiratory illness (WHO 2006) and 
chronic diseases (Epping-Jordan et al 2006).
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